OncoVista Innovative Therapies, Inc. – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 13 PAGES: 42

More Info
									OncoVista Innovative Therapies, Inc. – Product Pipeline
Review




            OncoVista Innovative Therapies, Inc. – Product
                     Pipeline Review – H2 2011


                                                                                          Reference Code: GMDHC02075CDB
                                                                                                 Publication Date: DEC 2011




OncoVista Innovative Therapies, Inc. – Product Pipeline Review – H2                       GMDHC02075CDB / Published DEC 2011
2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
OncoVista Innovative Therapies, Inc. – Product Pipeline
Review



Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
OncoVista Innovative Therapies, Inc. Snapshot ................................................................................................................................. 5
    OncoVista Innovative Therapies, Inc. Overview ............................................................................................................................ 5
    Key Information ............................................................................................................................................................................. 5
    Key Facts....................................................................................................................................................................................... 5
OncoVista Innovative Therapies, Inc. – Research and Development Overview ................................................................................. 6
    Key Therapeutic Areas .................................................................................................................................................................. 6
OncoVista Innovative Therapies, Inc. – Pipeline Review ................................................................................................................... 8
    Pipeline Products by Stage of Development ................................................................................................................................. 8
    Pipeline Products – Monotherapy ................................................................................................................................................. 9
    Pipeline Products – Combination Treatment Modalities .............................................................................................................. 10
OncoVista Innovative Therapies, Inc. – Pipeline Products Glance ................................................................................................... 11
    OncoVista Innovative Therapies, Inc. Clinical Stage Pipeline Products ...................................................................................... 11
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 11
    OncoVista Innovative Therapies, Inc. – Early Stage Pipeline Products ....................................................................................... 12
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 12
OncoVista Innovative Therapies, Inc. – Drug Profiles ...................................................................................................................... 13
    Cordycepin + Pentostatin ............................................................................................................................................................ 13
        Product Description................................................................................................................................................................. 13
        Mechanism of Action ............................................................................................................................................................... 13
        R&D Progress ......................................................................................................................................................................... 13
    OVI-117 ....................................................................................................................................................................................... 14
        Product Description................................................................................................................................................................. 14
        Mechanism of Action ............................................................................................................................................................... 14
        R&D Progress ......................................................................................................................................................................... 14
    OVI-123 ....................................................................................................................................................................................... 15
        Product Description................................................................................................................................................................. 15
        Mechanism of Action ............................................................................................................................................................... 15
        R&D Progress ......................................................................................................................................................................... 15
    Tubulin Isotype-Specific Anti-miotics ........................................................................................................................................... 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
OncoVista Innovative Therapies, Inc. – Pipeline Analysis ................................................................................................................ 17
    OncoVista Innovative Therapies, Inc. – Pipeline Products by Therapeutic Class ........................................................................ 17
    OncoVista Innovative Therapies, Inc. - Pipeline Products By Target........................................................................................... 18
    OncoVista Innovative Therapies, Inc. – Pipeline Products by Route of Administration ............................................................... 19
    OncoVista Innovative Therapies, Inc. – Pipeline Products by Molecule Type ............................................................................. 20
OncoVista Innovative Therapies, Inc. – Recent Pipeline Updates................................................................................................... 21
OncoVista Innovative Therapies, Inc. - Discontinued Pipeline Products .......................................................................................... 22


OncoVista Innovative Therapies, Inc. – Product Pipeline Review – H2                                                                    GMDHC02075CDB / Published DEC 2011
2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                      Page(2)
OncoVista Innovative Therapies, Inc. – Product Pipeline Review




    Discontinued Pipeline Product Profiles ........................................................................................................................................ 22
         OVI-237................................................................................................................................................................................... 22
OncoVista Innovative Therapies, Inc. – Company Statement .......................................................................................................... 23
OncoVista Innovative Therapies, Inc. – Locations And Subsidiaries ................................................................................................ 26
    Head Office.................................................................................................................................................................................. 26
    Other Locations & Subsidiaries ................................................................................................................................................... 26
Company's Recent Developments ................................................................................................................................................... 27
    OncoVista Innovative Therapies, Inc., Recent Developments ..................................................................................................... 27
         Nov 28, 2011: OncoVista Innovative Engages Oncology Therapeutic Development To Initiate Phase Ib Study Of Cordycepin
         In Patients With Refractory TdT Positive Leukemia ................................................................................................................ 27
         Jul 13, 2011: OncoVista Innovative Therapies Initiates Additional Safety Study Of OVI-117 .....
								
To top